BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 15, 2007
 |  BioCentury  |  Product Development

Nipping migraine in the bud

Rather than compete with triptans, which are marketed to treat migraine and work primarily by reducing the swelling and sensory nerve stimulation caused by migraine, Minster Pharmaceuticals plc says its tonabersat gap junction blocker has the kind of mechanism and safety profile that make it suitable for prophylaxis of migraine headaches. If so, it would compete with Topamax topiramate from Johnson & Johnson, which is marketed for prophylaxis of migraines and epilepsy.

Tonabersat, a once-daily oral compound, generated a superior response compared to placebo, the primary endpoint, in a Phase IIa trial in 124 patients, the company disclosed last week. A Phase IIb trial that will look at efficacy over four to five months is slated to start by mid-year.

"Tonabersat has been classified as a gap junction blocker, but we are still working on finding the precise molecule to which it...

Read the full 704 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >